What’s the current market cap for GSK stock?

GSK (GSK) has a market cap of $98B as of June 03, 2026.

What is the P/E ratio for GSK stock?

The price to earnings (P/E) ratio for GSK (GSK) stock is 25.63 as of June 03, 2026.

Does GSK stock pay dividends?

Yes, the GSK (GSK) stock pays dividends to shareholders. As of June 03, 2026, the dividend rate is $1.74545 and the yield is 3.84%. GSK has a payout ratio of 44.52% on a trailing twelve-month basis.

When is the next GSK dividend payment date?

The next GSK (GSK) dividend payment is scheduled for July 09, 2026.

What is the beta indicator for GSK?

GSK (GSK) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy GSK stock | $GSK Share Price

About GSK

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Ticker

$GSK

Sector

Health

Primary listing

NYSE

Employees

66,841

Headquarters

London, United Kingdom

Website

www.gsk.com

GSK Metrics

BasicAdvanced

$98bn

25.63

$1.91

0.30

$1.75

3.84%

What the Analysts think about GSK

Analyst ratings (Buy, Hold, Sell) for GSK stock.

Bulls say / Bears say

GSK posted core earnings per share of 46.5 pence for Q1 2026, surpassing analyst forecasts of 43.3 pence, driven by a record £1.03 billion in Shingrix vaccine sales and underpinning unchanged full-year guidance of 3–5% turnover growth (Reuters)

The company’s investigational antisense oligonucleotide bepirovirsen met the primary endpoints in its pivotal B-Well 1 and B-Well 2 Phase III trials, advancing filings for a potential functional cure in chronic hepatitis B and earning FDA Breakthrough Therapy and Priority Review designations with a PDUFA date of October 26, 2026 (Reuters)

Under CEO Luke Miels, GSK has executed bolt-on acquisitions of RAPT Therapeutics for $2.2 billion and Canada’s 35Pharma for $950 million, broadening and accelerating its late-stage oncology pipeline to drive long-term growth (Reuters)

GSK expects 2026 sales from its vaccines and general medicines units to decline by a low single-digit percentage, signaling headwinds in its core legacy portfolio and putting pressure on overall revenue growth this year (Reuters)

The company faces a looming patent cliff with its HIV medicine dolutegravir set to lose exclusivity in 2028, threatening erosion of a high-margin franchise that accounted for £X billion in sales in 2025 (Reuters)

Investors sold off GSK shares by over 8% on April 29 as they questioned whether one-off factors had inflated the headline Q1 beat, reflecting skepticism about the sustainability of the results (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 12 May 2026.

GSK Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

GSK Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

GSK News

AllArticlesVideos

UBS says UK stocks are better supported but not broadly so, as earnings lead while sentiment drags

Proactive Investors·11 hours ago

GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading

Proactive Investors·5 days ago

GSK Says Hepatitis B Drug Candidate Cured Some Patients in Late-Stage Trials

WSJ·7 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.